Global Economic Overview
The global economy demonstrated resilience in FY 2025-26, navigating persistent inflationary pressures, geopolitical tensions, and tightening monetary conditions across major economies. While advanced economies witnessed moderated growth, emerging marketsparticularly in Asiacontinued to exhibit relative strength, underpinned by robust domestic consumption and strategic policy interventions.
Global supply chains, previously disrupted by pandemic aftershocks and geopolitical conflicts, showed progressive normalization. Commodity prices stabilized, though energy markets remained volatile. Central banks across major economies began calibrating interest rate trajectories as inflation showed signs of cooling, setting the stage for a more conducive investment environment heading into FY 2026-27.
Indian Economic Landscape
Indias economy grew by 6.2% in Q3 FY25, with clear signs of recovery emerging as growth accelerated to 7.6% in Q4 FY25signalling a positive turnaround. The country ranked 5th globally in foreign direct investment inflows among developed and developing nations, reflecting strong investor confidence in Indias economic fundamentals.
The Union Budget for FY26 reinforced the governments commitment to infrastructure-led growth, with capital expenditure outlay increasing 10.0% to Rs. 11.21 lakh crore. Stronger revenue generationdriven by improved tax compliance, rising corporate profitability, and expanding economic activitysupported this elevated spending trajectory. Indias total exports of goods and services rose 5.5% to a record Rs. 69.8 lakh crore in FY25, underscoring the countrys strengthening external sector.
Inflationary pressures moderated through proactive government measures, flexible monetary policy, softening global commodity prices, and easing supply-chain bottlenecks. Port congestion reduced meaningfully, restoring supply network efficiency. These macroeconomic tailwinds create a favourable backdrop for consumer-facing industries, including pharmaceuticals and dermo cosmetics.
Industry Structure and Developments
Global Dermo cosmetic Industry
The global skincare and dermo cosmetic industry continues its robust growth trajectory, driven by heightened consumer awareness around skin health, preventive skincare, anti-aging solutions, pigmentation management, acne care, hair care, and sun protection. Consumers increasingly seek scientifically validated products combining pharmaceutical efficacy with cosmetic benefitsa trend that positions dermatologist-recommended brands favourably.
Indian Dermatology Market
The Indian dermatology market has demonstrated sustained resilience, growing at approximately 8% CAGR from FY 2021 to FY 2025. It remains one of the most stable therapeutic segments within Indian pharmaceuticals, spanning both prescription (Rx) and over-the-counter (OTC) channels.
Key Market Metrics:
| Segment | Growth Rate |
| Medical Dermatology | 8-10% per annum |
| Cosmetic Dermatology | 15-18% per annum |
Top 5 Sub-Segments ~65% of total market
The cosmetic dermatology segment is growing at nearly twice the rate of medical dermatology, reflecting shifting consumer preferences toward aesthetic and preventive skincare. Within dermatology, cosmetic applications witnessed 28% growth in 2021 alone, with a sustained CAGR of approximately 13%.
Top Five Dermatology Sub-Segments:
| Sub-Segment | Market Share |
| Moisturizing & Protective Agents | 15-16% |
| Anti-Acne & Anti-Scarring | 12-13% |
| Topical Antibiotics | 12-13% |
| Anti-Inflammatory | 3-5% |
| Antifungals | 1-2% |
The Indian dermatology market is estimated at Rs. 16,000 crore KPMG Report January 2026 and is projected to grow at 11-12% annually. Growth drivers include increasing prevalence of skin conditions due to pollution, rising demand for aesthetic dermatology procedures, growing disposable incomes, expanding population, and lifestyle changes.
Indian Pharmaceutical Industry
The total annual turnover of pharmaceuticals in FY24 reached Rs. 4.17 lakh crore, growing at an average rate of 10.1% over the preceding five years. The dermatology segment outpaces broader pharmaceutical growth, attracting significant strategic and private equity interest. Leading players are accelerating new product launches and science-based solutions to capitalize on this momentum.
Key Industry Drivers
- Increasing incidence of dermatological disorders due to pollution, stress, and lifestyle changes
- Rising awareness regarding preventive skincare and early intervention
- Growing preference for dermatologist-recommended products over conventional cosmetics
- Expansion of organized dermatology clinics and aesthetic centres across urban and semi-urban India
- Growth in e-commerce and digital healthcare platforms, improving product accessibility
- Increased consumer focus on scientifically backed formulations and clinical efficacy
- Enhanced access to dermatologist consultations, including via telemedicine.
Company Overview
Amwill Healthcare operates in the dermatology and dermo cosmetic segment, offering scientifically formulated skincare products recommended by dermatologists and healthcare professionals. The Company addresses diverse skin concernsincluding acne, pigmentation, aging, photoprotection, hydration, and sensitive skin managementthrough its comprehensive product portfolio.
Segment-wise Performance
Product Portfolio
The Company maintains a diversified portfolio across Eleven Therapy, comprising 112 products:
| Segment | Number of Products |
| Sunscreen | 4 |
| Dry Skin | 13 |
| Hair Care | 17 |
| Skin Lightening | 11 |
| Anti Acne | 20 |
| Anti-Fungal | 11 |
| Lip Care | 11 |
| Steroid | 11 |
| Anti Histamine | 10 |
| Anti-Oxidant | 2 |
| Cosmetic Procedure | 3 |
| Vitiligo | 4 |
| Anti-Bacterial | 3 |
| Eye Care | 1 |
| Hyperhidrosis | 1 |
Revenue Contribution by Segment FY 2025-26
| Therapy Name | March, 2026 Revenue in Lacs | March, 2026 % of total revenue |
| Sunscreen | 1143.71 | 25.14 |
| Dry Skin | 811.35 | 17.83 |
| Hair Care | 610.37 | 13.42 |
| Skin Lightening | 572.31 | 12.58 |
| Anti Acne | 340.63 | 7.49 |
| Anti-Fungal | 239.14 | 5.26 |
| Lip Care | 200.82 | 4.41 |
| Steroid | 175.87 | 3.87 |
| Anti Histamine | 105.99 | 2.33 |
| Anti-Oxidant | 102.07 | 2.24 |
| Cosmetic Procedure | 99.86 | 2.2 |
| Vitiligo | 70.34 | 1.55 |
| Anti-Bacterial | 48.2 | 1.06 |
| Eye Care | 19.76 | 0.43 |
| Hyperhidrosis | 8.79 | 0.19 |
| Total | 4549.23 | 100 |
Skin care remains the dominant revenue contributor, aligned with broader market trends favouring dermatologist-recommended skincare solutions. Hair care represents a significant and growing segment, consistent with industry projections of double-digit growth in this category.
Financial Performance
Financial Highlights FY 2025-26
| Particulars | FY 2025-26 (Rs Lakhs) | FY 2024-25 (Rs Lakhs) | Change |
| Total Income | 4,841.14 | 4,128.88 | 17.25% |
| Revenue from Operations | 4,549.23 | 4,058.16 | 12.10% |
| Total Expenses | 3,304.53 | 2,938.56 | 12.45% |
| Profit Before Tax (PBT) | 1,536.61 | 1,190.32 | 29.09% |
| Profit After Tax (PAT) | 1,142.13 | 1,073.01 | 6.44% |
| Tax Expense | 399.75 | 122.51 | 226.29% |
| Deferred Tax Credit | -5.27 | -5.20 | 1.24% |
| Earnings Per Share (Rs) | 5.71 | 6.63 | -13.91% |
Key Observations:
- Revenue Growth: Total income increased by 17.25% to Rs. 4,841.14 lakhs, reflecting improved market penetration and product mix optimization.
- Profitability: PBT grew robustly by 29.10% to Rs. 1,536.61 lakhs, demonstrating operational leverage despite rising expenses.
- PAT Growth: Net profit increased by 6.44% to Rs. 1,142.13 lakhs. There is a moderate PAT growth which is a reflection of increased turnover during the year.
- EPS Decline: Earnings per share decreased to Rs. 5.71 from Rs. 6.63, primarily attributable to equity expansion during the year.
- Expense Management: Total expenses increased by 12.45%, moderate increase in expenses is attributable to enhanced operational activities aligned with growth initiatives.
The Company maintained profitability while investing in capabilities to support future expansion. Management is implementing strategic initiatives focused on revenue optimization, cost efficiency, and sustainable profitability.
Key Financial Ratios
| Ratio | FY 2025-26 | FY 2024-25 | Variance (%) | Reasons (if >25% variances) |
| Return on Net Worth (%) | 14.17% | 15.50% | -9% | NA |
| Inventory Turnover (times) | 19.66% | 22.08% | -11% | NA |
| Operating Profit Margin (%) | 30.61% | 27.63% | NA | |
| Current Ratio (times) | 12.39% | 11.11% | 12% | NA |
| Net Profit Margin (%) | 25.11% | 26.40% | -5% | NA |
| Debtors Turnover | NA | NA | NA | NA |
| Interest Coverage | NA | NA | NA | NA |
| Debt Equity Ratio | NA | NA | NA | NA |
Opportunities
The Company identifies significant opportunities in:
- Geographic Expansion: Increasing penetration in Tier II and Tier III cities, where dermatological awareness is rising rapidly.
- Product Innovation: Launching differentiated, clinically validated formulations addressing emerging skin and hair care concerns.
- Anti-Aging & Photoprotection: Capitalizing on growing demand for preventive skincare and sun protection products.
- Prescription-Supportive Cosmeceuticals: Rising acceptance among dermatologists and consumers.
- Digital Channels: Strengthening e-commerce presence and digital marketing capabilities
- International Markets: Exploring export opportunities in emerging and regulated international markets.
- Clinical Research: Developing innovative formulations supported by rigorous clinical validation.
Risks and Concerns
The Company operates in specialized fields of dermatology, trichology, and cosmetology, exposing it to several risks:
- Regulatory and Compliance Risks: Stringent product approval requirements, evolving health and safety regulations, and restrictions on marketing claims necessitate continuous compliance vigilance.
- Product Safety and Efficacy Risks: Risks of adverse reactions, long-term side effects, and challenges in clinical validation require robust quality assurance and pharmacovigilance systems.
- Market Risks: Intense competition, shifting consumer preferences, and pricing pressures persist across the dermo cosmetic segment.
- Intellectual Property Risks: Patent protection and ensuring adequate returns on R&D investment remain ongoing concerns.
- Supply Chain and Manufacturing Risks: Raw material availability, quality control, and third-party manufacturing dependency can impact operations.
- Reputational Risks: Consumer trust is paramount; social media influence amplifies both positive and negative perceptions.
- Technological Disruption: Rapid advancements in formulation technology and digital transformation require continuous adaptation.
- Financial Risks: Currency fluctuations from potential global operations may impact profitability.
- External Factors: Economic downturns, global health crises, and evolving environmental compliance obligations pose additional challenges.
- Human Resources and Industrial Relations: The Company continues to prioritize human resources as a key enabler of operational excellence and innovation. During the year, targeted recruitment strengthened internal capabilities, particularly in Sales and Marketing functions supporting business expansion.
Employee Headcount
| Department | FY 2024-25 | FY 2025-26 | Change |
| Directors | 2 | 2 | - |
| Compliance Team | 1 | 1 | - |
| Business Development Team | 3 | 1 | -2 |
| Accounts Team | 3 | 4 | 1 |
| Human Resource Team | 1 | 1 | - |
| Graphics Team | 1 | 1 | - |
| Inventory Management Team | 5 | 4 | -3 |
| Logistics Management Team | 3 | 1 | -2 |
| Payroll Management Team | 2 | 0 | -2 |
| Product Management Team | 1 | 0 | -1 |
| Purchase Management Team | 2 | 0 | -2 |
| Sales & Marketing Team | 64 | 72 | 8 |
| Total | 88 | 88 |
Industrial relations remained cordial throughout the year, with no disputes or disruptions reported. The Company maintains a safe, inclusive, and engaging work environment, investing in employee development, compliance training, and leadership capability building.
HR Strategy Going Forward:
- Performance-linked retention programs
- Digital workforce management systems
- Scalable training initiatives to support future growth
Outlook
The Company remains optimistic about its growth trajectory in the dermatology, trichology, and cosmetology segments. Increasing consumer awareness, rising demand for specialized skincare and haircare solutions, and the expanding wellness and aesthetic market in India and overseas provide a favourable operating environment.
Strategic Priorities:
- Distribution Network Enhancement: Expanding geographic reach and deepening market penetration.
- Digital Footprint Expansion: Strengthening e-commerce capabilities and digital marketing presence.
- Product Innovation: Launching differentiated, clinically validated products aligned with consumer needs.
- Sustainable Formulations: Focusing on dermatologically safe, science-backed formulations meeting global regulatory standards.
- Dermatologist Engagement: Expanding programs to strengthen relationships with healthcare professionals.
- Research & Development: Continuing investment in product development capabilities.
- Quality and Compliance: Maintaining investments in quality systems, regulatory compliance, and patient education initiatives.
While macroeconomic uncertainties, regulatory changes, and evolving consumer preferences may pose challenges, the Company remains committed to operational excellence, brand trust, and customer-centric innovation. Continuous investment in people, processes, and technology will be pivotal in driving long-term value creation.
With a solid foundation, strong brand portfolio, and strategic initiatives underway, management anticipates improved performance in coming years and remains confident in the Companys ability to deliver sustainable and profitable growth.
Internal Control Systems and Adequacy
The Company has established robust internal control systems commensurate with the size and nature of its operations. These controls ensure:
- Safeguarding of assets
- Prevention and detection of fraud and error
- Accuracy and completeness of accounting records
- Timely preparation of reliable financial information
Internal controls are reviewed periodically and strengthened as necessary. The Audit Committee regularly reviews the adequacy and effectiveness of internal control systems and recommends improvements.
Cautionary Statement
Statements in this Management Discussion and Analysis describing the Companys objectives, projections, estimates, and expectations may constitute "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results could differ materially from those expressed or implied due to various factors, including but not limited to economic conditions affecting demand and supply, government regulations, natural calamities, and other factors beyond the Companys control. The Company assumes no responsibility to publicly amend, modify, or revise any such statements based on subsequent developments, information, or events.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.